[1] SINGER M,DEUTSCHMAN C S,SEYMOUR C W,et al.The third international consensus definitions for sepsis and septic shock (sepsis-3)[J].JAMA,2016,315(8):801-810.
[2] SKUBE S J,KATZ S A,CHIPMAN J G,et al.Acute kidney injury and sepsis[J].Surg Infect (Larchmt),2018,19(2):216-224.
[3] 李一鸣,祝媛,张婧,等.脓毒症与急性肾损伤[J].中华医学杂志,2021,101(17):1210-1213.
[4] BAGSHAW S M,UCHINO S,BELLOMO R,et al.Septic acute kidney injury in critically ill patients:clinical characteristics and outcomes[J].Clin J Am Soc Nephrol,2007,2(3):431-439.
[5] BAGSHAW S M,GEORGE C,BELLOMO R,et al.Early acute kidney injury and sepsis:a multicentre evaluation[J].Crit Care,2008,12(2):R47.
[6] HOSTE E A,BAGSHAW S M,BELLOMO R,et al.Epidemiology of acute kidney injury in critically ill patients:the multinational AKI-EPI study[J].Intensive Care Med,2015,41(8):1411-1423.
[7] UCHINO S,KELLUM J A,BELLOMO R,et al.Acute renal failure in critically ill patients:a multinational,multicenter study[J].JAMA,2005,294(7):813-818.
[8] LIVIGNI S,BERTOLINI G,ROSSI C,et al.Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock:a multicenter randomised controlled clinical trial[J].BMJ Open,2014,4(l):e3536.
[9] MARIANO F,HOLLO Z,DEPETRIS N,et al.Coupled-plasma filtration and adsorption for severe burn patients with septic shock and acute kidney injury treated with renal replacement therapy[J].Burns,2020,46(1):190-198.
[10] LI X,LIU C,MAO Z,et al.Effectiveness of polymyxin B-immobilized hemoperfusion against sepsis and septic shock:a systematic review and meta-analysis[J].J Crit Care,2021,63:187-195.
[11] 刘雪媛,杨梁,刘朝发.脓毒症患者预后相关危险因素的综合分析[J].现代医学,2023,51(3):294-298.
[12] 明颖,闫妹姝,刘秋霞,等.脓毒症患者血清降钙素原、炎症因子水平与APACHEⅡ、SOFA评分的相关性[J].现代医学,2020,48(3):357-361.
[13] CHARLSON M,SZATROWSKI T P,PETERSON J,et al.Validation of a combined comorbidity index[J].J Clin Epidemiol,1994,47(11):1245-1251.
[14] NEWMAN M,HANSON H,SCHLIEP K,et al.Validating older adult morbidity trajectories using multiple comorbidity indices[J].Innov Aging,2020,4(S1):174-175.
[15] OLTEAN S,ŢǎTULESCU D,BONDOR C,et al.Charlson's weighted index of comorbidities is useful in assessing the risk of death in septic patients.[J].J Crit Care,2012,27:370-375.
[16] 盛松,张艳虹,马杭琨,等.查尔森合并症指数对合并急性肾损伤并接受连续肾脏替代治疗的脓毒症患者死亡风险的评估价值[J].临床急诊杂志,2021,22(11):764-771.
[17] CHOI G,GOMERSALL C D,TIAN Q,et al.Principles of antibacterial dosing in continuous renal replacement therapy[J].Crit Care Med,2009,37(7):2268-2282.
[18] AKHOUNDI A,SINGH B,VELA M,et al.Incidence of adverse events during continuous renal replacement therapy[J].Blood Purif,2015,39(4):333-339.
[19] GAUDRY S,HAJAGE D,SCHORTGEN F,et al.Initiation strategies for renalreplacement therapy in the intensive care unit[J].N Engl J Med,2016,375(2):122-133.
[20] KHWAJA A.KDIGO clinical practice guidelines for acute kidney injury[J].Nephron Clin Pract,2012,120(4):c179-c184.
[21] MARSHALL M R,张凌,王敏敏,等.oXiris-内毒素吸附技术的临床应用[J].华西医学,2018,33(7):797-800.
[22] SAMMAN K N,BAALBAKI H,BOUCHARD J,et al.Continuous renal replacement therapy with oXiris® membrane in severe ebstein-barr virus-mediated hemophagocytic lymphohistiocytosis:a case report[J].Blood Purif,2021,50:578-581.
[23] WEI T,CHEN Z,LI P,et al.Early use of endotoxin absorption by oXiris in abdominal septic shock:a case report.[J].Medicine,2020,99(28):e19632. |